How gut microbes respond to medicines and inflammation
From here to eternity: gut microbial response to drug therapy and inflammation
['FUNDING_OTHER'] · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · NIH-11178415
The team is finding which gut microbes and microbial genes change during inflammation or when people take medications to learn how those changes affect health for people with inflammatory conditions.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NORTHERN CALIFORNIA INSTITUTE/RES/EDU (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11178415 on ClinicalTrials.gov |
What this research studies
From my perspective as a patient, this project looks at how the genes of gut microbes shift when the body is inflamed or when medicines are used. Researchers will use microbial gene sequencing, laboratory experiments, and comparisons across different drug and inflammation conditions to spot which microbial genes respond. They will connect those microbial responses to how the host handles inflammation and drug effects, using models and samples to trace cause-and-effect. The goal is to point to microbe-targeted approaches like tailored live biotherapeutics or small-molecule inhibitors.
Who could benefit from this research
Good fit: People with systemic inflammatory conditions (for example inflammatory bowel disease or other inflammatory disorders) or those taking drugs that affect the gut microbiome would be most relevant to this research.
Not a fit: People without inflammatory conditions or whose treatments do not affect the gut microbiome are unlikely to get direct benefits in the near term.
Why it matters
Potential benefit: If successful, the work could point to new microbiome-based treatments or tests that predict who will respond better to medicines during inflammation.
How similar studies have performed: Some microbiome therapies, such as fecal transplants for C. difficile infection, have been successful, but pinpointing specific microbial genes that drive drug and inflammation responses is a newer and less-tested area.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- NORTHERN CALIFORNIA INSTITUTE/RES/EDU — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAYAK, RENUKA RAJENDRA — NORTHERN CALIFORNIA INSTITUTE/RES/EDU
- Study coordinator: NAYAK, RENUKA RAJENDRA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.